Table I. Patient and control donor characteristics
CodeDonationGenderAgeDiseaseNo. of American College of Rheumatology CriteriaModified SLEDAI-2k (SLEDAI-2k)Anti-dsDNA (<20 U/ml)TreatmentMatched ControlBarcode NumberBarcode Metals
Pat_001Whole bloodF55SLE5/116 (6)18.4HCQ 200 mg/d, Pred. 5 mg/dND_0511104Pd/106Pd
Pat_002Whole bloodF35SLE6/1110 (14)57.9HCQ 200 mg/d, Pred. 5 mg/dND_0502104Pd/108Pd
Pat_003Whole bloodM35SLE8/1112 (16)>200HCQ 200 mg/d, Pred. 20 mg/dND_0493104Pd/110Pd
Pat_004Whole bloodM35SLE7/116 (10)27MTX 15 mg/wk, Pred. 5 mg/d, HCQ 200 mgND_0494104Pd/196Pt
Pat_005Whole bloodF39SLE7/1120 (24)>200Pred. 30 mg/d, HCQ 200 mg/dND_0515106Pd/108Pd
Pat_006Whole bloodM72IBMBaricitinib6106Pd/110Pd
ND_048Whole bloodM487106Pd/196Pt
ND_049Whole bloodM398108Pd/110Pd
ND_050Whole bloodF319108Pd/196Pt
ND_051Whole bloodF4210110Pd/196Pt
  • —, does not apply.

  • F, female; HCQ, hydroxychloroquine; IBM, inclusion body myositis; M, male; MTX, methotrexate; Pred., prednisone.